Promega Corporation

Compound Interference of CellTiter-Glo® vs PE ATPlite™ 1 Step Poster




Brad Hook and Trista Schagat
Promega Corporation, 2800 Woods Hollow Road, Madison, WI USA 53711

Reducing the number of false positives in a high-throughput screen is a key goal for any researcher trying to minimize downstream efforts. Luciferase-based systems are used widely as reporters for drug screens; however, compounds in a library can inhibit luciferase, resulting in false positives. Ultra-Glo™ rLuciferase, an evolved luciferase from the firefly, Photuris pennsylvanica, is less sensitive to compound inhibition than wild-type firefly luciferase. In this study, we directly compare the abilities of the Promega CellTiter-Glo® Luminescent Cell Viability Assay, an Ultra-Glo™ rLuciferase-based luminescent ATP detection system, and the Perkin Elmer ATPlite™ 1step assay to resist common commercial luciferase inhibitors. The CellTiter-Glo® Assay has greater than 80% activity for 5 out of the 7 compounds at an inhibitor concentration of 10μM; whereas, ATPlite™ 1step has 80% activity for only 1 out of 7 compounds at the same inhibitor concentrations.

Document Icon Download the poster PDF (399kb)

  • Part# PS143
  • Printed in USA.

Prefer a different language?

Your country is set to Brazil. Your language is set to Português. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.